Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia.
From the U.S. FDA-approved label for Cytarabine. Full label: DailyMed.
Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.
From the U.S. FDA-approved label for Cytarabine. Full label: DailyMed.
Cytarabine injection is not active orally. The schedule and method of administration varies with the program of therapy to be used. Cytarabine injection may be given by intravenous infusion or injection, subcutaneously, or intrathecally (preservative free preparation only).
Directions from the U.S. FDA-approved label for Cytarabine — your doctor or pharmacist may advise differently.
Cytarabine is contraindicated in those patients who are hypersensitive to the drug.
Excerpt from the U.S. FDA-approved label for Cytarabine. Talk to a pharmacist or doctor before use.
(See boxed WARNING ) Cytarabine is a potent bone marrow suppressant. Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression. Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily. Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.
Warnings and precautions excerpt from the U.S. FDA-approved label for Cytarabine — not a complete list. Talk to a pharmacist or doctor before use.
Expected Reactions Because cytarabine is a bone marrow suppressant, anemia, leukopenia, thrombocytopenia, megaloblastosis and reduced reticulocytes can be expected as a result of administration with cytarabine. The severity of these reactions are dose and schedule dependent. Cellular changes in the morphology of bone marrow and peripheral smears can be expected.
Excerpt from the U.S. FDA-approved label for Cytarabine — not a complete list. Talk to a pharmacist or doctor about side effects.
Conditions Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from light. Retain in carton until time of use. Discard unused portion. Isotonic Solution Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.
Storage information from the U.S. FDA-approved label for Cytarabine.
What is Cytosar?
Cytosar 100mg Injection is a Cytarabine medicine made by Pfizer Ltd. It comes as 100mg Injection.
What is Cytosar used for?
According to its FDA label, Cytarabine is used for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients.
What is the generic name of Cytosar?
The generic name of Cytosar is Cytarabine.
What are the side effects of Cytarabine?
Expected Reactions Because cytarabine is a bone marrow suppressant, anemia, leukopenia, thrombocytopenia, megaloblastosis and reduced reticulocytes can be expected as a result of administration with cytarabine.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
